Send to:

Choose Destination
See comment in PubMed Commons below
Clin Infect Dis. 1996 Apr;22 Suppl 1:S3-13; discussion S13-4.

Antimicrobial activity of rifabutin.

Author information

  • 1Department of Internal Medicine, Ohio State University, Columbus 43210-1240, USA.


Rifabutin is a spiro-piperidyl-rifamycin derived from rifamycin-S. It is structurally related to rifampin and shares many of its properties. Rifabutin has a broad spectrum of antimicrobial activity. It is considerably more active than rifampin in vitro against the Mycobacterium avium complex (MAC), Mycobacterium tuberculosis, and Mycobacterium leprae. It also is active against most atypical mycobacteria, including Mycobacterium kansasii, but Mycobacterium chelonae is relatively resistant. Rifabutin also is active against staphylococci, group A streptococci, Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae, Haemophilus ducreyi, Campylobacter jejuni, Helicobacter pylori, Chlamydia trachomatis, and Toxoplasma gondii. It has poor activity against Enterobacteriaceae and Pseudomonas species. This review focuses on the antimicrobial profile of rifabutin in relation to its pharmacological properties. Special emphasis is placed on its in vitro activity against MAC and other mycobacteria, its efficacy in cell culture and animal models, and its potential as a component of multidrug therapy for mycobacterial and other infectious diseases.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk